NCT06992258 2026-03-17
FRUITION
Criterium, Inc.
Phase 2 Recruiting
Clinical Trials
3 trialsNCT06562543 2026-02-27
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
Takeda
Phase 4 Recruiting
NCT07136077 2026-02-27
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting